All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Timothy M. SchmidtDuring the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy M. Schmidt, University of Wisconsin-Madison, Madison, US. We asked, Where does carfilzomib fit in the current multiple myeloma (MM) treatment landscape?
Where does carfilzomib fit in the current MM treatment landscape?
In this video, Schmidt discusses the selective proteasome inhibitor carfilzomib and its potential role in treating patients with high-risk MM after the results presented this year. He discusses carfilzomib in combination with immunomodulatory drugs and in the treatment of early relapsed/refractory (R/R) MM, especially for lenalidomide and/or bortezomib-refractory disease. Lastly, he mentions the clinical trials ENDURANCE (NCT01863550) and CLARION (NCT01818752) which are both phase III studies evaluating carfilzomib in newly diagnosed MM patients.
Your opinion matters
HCPs, what do you view as the greatest barrier to the use of belantamab mafodotin combinations in clinical practice?